KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) Other Non Operating Income (2016 - 2025)

Medpace Holdings' Other Non Operating Income history spans 11 years, with the latest figure at -$158000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 125.44% year-over-year to -$158000.0; the TTM value through Dec 2025 reached -$5.3 million, down 231.61%, while the annual FY2025 figure was -$5.3 million, 231.61% down from the prior year.
  • Other Non Operating Income reached -$158000.0 in Q4 2025 per MEDP's latest filing, up from -$489000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $5.6 million in Q3 2022 to a low of -$2.9 million in Q2 2025.
  • Average Other Non Operating Income over 5 years is $423650.0, with a median of $443000.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 772.08% in 2022, then plummeted 2061.65% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $1.1 million in 2021, then plummeted by 279.89% to -$2.0 million in 2022, then soared by 178.76% to $1.5 million in 2023, then plummeted by 59.75% to $621000.0 in 2024, then tumbled by 125.44% to -$158000.0 in 2025.
  • Per Business Quant, the three most recent readings for MEDP's Other Non Operating Income are -$158000.0 (Q4 2025), -$489000.0 (Q3 2025), and -$2.9 million (Q2 2025).